Literature DB >> 15958083

Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.

M R J Green1, A S M Kennell, M J Larche, M H Seifert, D A Isenberg, M R Salaman.   

Abstract

Natural killer (NK) cell cytotoxic activity and cell frequency, expressed as a percentage of total lymphocytes, have been determined in peripheral blood mononuclear cells from first-degree relatives of patients with systemic lupus erythematosus (SLE), the patients themselves, a group of rheumatoid arthritis (RA) patients and controls. Low levels of killing activity relative to controls were found in some members of all groups with the extent of depression falling into two ranges. Moderate reductions were seen in female (3/31, 10%) and male (4/14, 29%) relatives of SLE patients, female (12/60, 20%) and male (3/4, 75%) SLE patients and female RA patients (6/17, 35%). A more profound depression of killing activity was confined to other female SLE patients (15/60, 25%). There were strong correlations in all groups between killing activity and percentage of NK cells, but analysis of the ratio of these parameters and studies with purified preparations of NK cells suggest that the reduced activity in SLE frequently involves a defect in the killing capacity of the individual cells in addition to the reduced levels of NK cells. Azathioprine (AZA), which was used in treatment of 12 SLE patients, was invariably associated with low values of killing activity. It appears to substantially reduce the percentage of NK and B cells in an action unconnected with the NK cell abnormalities associated with SLE. The finding of low killing activity in relatives and a correlation between their activity and that of their patients support the view that NK cell deficiency is a genetic determinant of SLE. NK cells in SLE may produce insufficient levels of cytokines required for the regulation of IgG production.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958083      PMCID: PMC1809425          DOI: 10.1111/j.1365-2249.2005.02822.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

Review 1.  Azathioprine: current status and future considerations.

Authors:  Rokea A El-Azhary
Journal:  Int J Dermatol       Date:  2003-05       Impact factor: 2.736

2.  The inhibition of NK cell function by azathioprine during the treatment of patients with rheumatoid arthritis.

Authors:  R Cseuz; G S Panayi
Journal:  Br J Rheumatol       Date:  1990-10

3.  Association tests with systemic lupus erythematosus (SLE) of IL10 markers indicate a direct involvement of a CA repeat in the 5' regulatory region.

Authors:  S D' Alfonso; M Giordano; M Mellai; M Lanceni; N Barizzone; M Marchini; R Scorza; M G Danieli; M Cappelli; P Rovere; M G Sabbadini; P Momigliano-Richiardi
Journal:  Genes Immun       Date:  2002-12       Impact factor: 2.676

Review 4.  The role of NK cells in autoimmune disease.

Authors:  Alan G Baxter; Mark J Smyth
Journal:  Autoimmunity       Date:  2002-02       Impact factor: 2.815

Review 5.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

6.  Reassuring effect of pravastatin on natural killer cell activity in stable renal transplant patients.

Authors:  L M Vaessen; P P van Miert; T van Gelder; J N Ijzermans; W Weimar
Journal:  Transplantation       Date:  2001-04-27       Impact factor: 4.939

7.  Natural killer cell activity in the systemic connective tissue diseases.

Authors:  R Gonzalez-Amaro; J Alcocer-Varela; D Alarcón-Segovia
Journal:  J Rheumatol       Date:  1988-08       Impact factor: 4.666

Review 8.  The genetics of lupus.

Authors:  F K Tan; F C Arnett
Journal:  Curr Opin Rheumatol       Date:  1998-09       Impact factor: 5.006

Review 9.  The genetics of systemic lupus erythematosus: putting the pieces together.

Authors:  J A Kelly; K L Moser; J B Harley
Journal:  Genes Immun       Date:  2002-10       Impact factor: 2.676

10.  A longitudinal study of the influence of azathioprine on natural killer cell activity.

Authors:  B K Pedersen; J M Beyer
Journal:  Allergy       Date:  1986-05       Impact factor: 13.146

View more
  35 in total

1.  Dynamic changes in the numbers of different subsets of peripheral blood NK cells in patients with systemic lupus erythematosus following classic therapy.

Authors:  Hongshuang Ma; Ling Zhao; Zhenyu Jiang; Yanfang Jiang; Li Feng; Zhuang Ye
Journal:  Clin Rheumatol       Date:  2014-07-15       Impact factor: 2.980

2.  Gene expression profiles in a rabbit model of systemic lupus erythematosus autoantibody production.

Authors:  Geeta Rai; Satyajit Ray; Jacqueline Milton; Jun Yang; Ping Ren; Richard Lempicki; Rose G Mage
Journal:  J Immunol       Date:  2010-09-03       Impact factor: 5.422

3.  Natural killer cell expression of Ki67 is associated with elevated serum IL-15, disease activity and nephritis in systemic lupus erythematosus.

Authors:  K Hudspeth; S Wang; J Wang; S Rahman; M A Smith; K A Casey; Z Manna; M Sanjuan; R Kolbeck; S Hasni; R Ettinger; R M Siegel
Journal:  Clin Exp Immunol       Date:  2019-03-19       Impact factor: 4.330

Review 4.  Natural killer cells as indispensable players and therapeutic targets in autoimmunity.

Authors:  Fu-Dong Shi; Qinghua Zhou
Journal:  Autoimmunity       Date:  2010-08-11       Impact factor: 2.815

5.  Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus.

Authors:  Wen-Xian Li; Hai-Feng Pan; Jian-Li Hu; Chang-Zhong Wang; Ning Zhang; Jing Li; Xiang-Pei Li; Jian-Hua Xu; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2009-12-10       Impact factor: 2.980

6.  Identification of new SLE-associated genes with a two-step Bayesian study design.

Authors:  D L Armstrong; A Reiff; B L Myones; F P Quismorio; M Klein-Gitelman; D McCurdy; L Wagner-Weiner; E Silverman; J O Ojwang; K M Kaufman; J A Kelly; J T Merrill; J B Harley; S-C Bae; T J Vyse; G S Gilkeson; P M Gaffney; K L Moser; C Putterman; J C Edberg; E E Brown; J Ziegler; C D Langefeld; R Zidovetzki; C O Jacob
Journal:  Genes Immun       Date:  2009-05-14       Impact factor: 2.676

7.  NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Eliana A G Reis; Daniel A Athanazio; Isabella Lima; Natália Oliveira e Silva; Jorge Clarencio S Andrade; Ronden N Jesus; Lúcio M Barbosa; Mitermayer G Reis; Mittermayer B Santiago
Journal:  Rheumatol Int       Date:  2008-09-28       Impact factor: 2.631

8.  NK cells dysfunction in systemic lupus erythematosus: relation to disease activity.

Authors:  Ana Henriques; Luís Teixeira; Luís Inês; Tiago Carvalheiro; Ana Gonçalves; António Martinho; Maria Luísa Pais; José António Pereira da Silva; Artur Paiva
Journal:  Clin Rheumatol       Date:  2013-02-02       Impact factor: 2.980

9.  Serendipitous evidence of T lymphocyte activation in close female relatives of patients with systemic lupus erythematosus.

Authors:  M R J Green; A S M Kennell; M J Larche; M H Seifert; D A Isenberg; M R Salaman
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

10.  Pattern of DAP12 expression in leukocytes from both healthy and systemic lupus erythematosus patients.

Authors:  Nicolas Schleinitz; Laurent Chiche; Sophie Guia; Gaëlle Bouvier; Julie Vernier; Alexis Morice; Elisabeth Houssaint; Jean Robert Harlé; Gilles Kaplanski; Félix A Montero-Julian; Frédéric Vély
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.